Details for Patent: 8,759,516

Title:	Inhibitors of Bruton's tyrosine kinase
Abstract:	Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:	Jul 26, 2013
Application Number:	13/952,531
Claims:	1. A process for the preparation of an amino protected form of 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperi- din-1-yl)prop-2-en-1-one (compound 4) comprising: treatment of compound 3: ##STR00057## wherein compound 3 exists in the R or S configuration or mixture thereof and the primary amino group in compound 3 is protected with an amino protecting group, with an acid and then a base, followed by coupling with acryloyl chloride to give compound 4: ##STR00058## wherein compound 4 is in the R or S configuration or mixture thereof and the primary amino group in compound 4 is protected with an amino protecting group. 2. The process of claim 1, wherein the acid is hydrochloric acid. 3. The process of claim 1, wherein the acid is hydrochloric acid in dioxane. 4. The process of claim 1, wherein the process comprises treatment of compound 3 with hydrochloric acid in dioxane, followed by concentration of the reaction to dryness and coupling with acryloyl chloride. 5. The process of claim 1, wherein compound 4 is washed with aqueous citric acid and brine. 6. The process of any one of claims 1-5, wherein compound 4 is purified by flash chromatography. 7. The process of claim 1, wherein compound 3 exists as a mixture of the R and S configuration and compound 4 exists as a mixture of the R and S configuration. 8. The process of claim 1, wherein compound 3 exists in the R configuration and compound 4 exists in the R configuration. 9. The process of claim 1, wherein compound 3 exists in the S configuration and compound 4 exists in the S configuration. 10. The process of claim 1 wherein the amino protecting group is a carbamate group or an amide group. 11. The process of claim 10 wherein the amino protecting group is a carbamate group. 12. The process of claim 11 wherein the carbamate group is selected from methylcarbamate, ethylcarbamate, 9-fluoromethyl carbamate, 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate, 4-methoxyphenacyl carbamate, 2,2,2-trichloroethyl carbamate, 2-trimethylsilylethyl carbamate, 2-phenylethyl carbamate, 1,1-dimethyl-2-bromoethyl carbamate, 1,1-dimethyl-2-chloroethyl carbamate, 1-methyl-1-(4-biphenyl)ethyl carbamate, t-butyl carbamate, 1-adamantyl carbamate, vinyl carbamate, allyl carbamate, 1-isopropylallyl carbamate, cinnamyl carbamate, 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, benzyl carbamate, p-methoxybenzyl carbamate, p-nitrobenzyl carbamate, 2,4-dichlorobenzyl carbamate, and diphenylmethyl carbamate. 13. The process of claim 10 wherein the amino protecting group is an amide group. 14. The process of claim 13 wherein the amide group is selected from formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, pent-4-enamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl, benzamide, and p-phenylbenzamide. 15. A compound having the structure: ##STR00059## wherein the primary amino group is protected with an amino protecting group. 16. A compound having the structure: ##STR00060## wherein the primary amino group is protected with an amino protecting group. 17. The compound of claim 15 or claim 16 wherein the amino protecting group is a carbamate group or an amide group. 18. The compound of claim 17 wherein the amino protecting group is a carbamate group. 19. The compound of claim 18 wherein the carbamate group is selected from methylcarbamate, ethylcarbamate, 9-fluoromethyl carbamate, 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate, 4-methoxyphenacyl carbamate, 2,2,2-trichloroethyl carbamate, 2-trimethylsilylethyl carbamate, 2-phenylethyl carbamate, 1,1-dimethyl-2-bromoethyl carbamate, 1,1-dimethyl-2-chloroethyl carbamate, 1-methyl-1-(4-biphenyl)ethyl carbamate, t-butyl carbamate, 1-adamantyl carbamate, vinyl carbamate, allyl carbamate, 1-isopropylallyl carbamate, cinnamyl carbamate, 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, benzyl carbamate, p-methoxybenzyl carbamate, p-nitrobenzyl carbamate, 2,4-dichlorobenzyl carbamate, and diphenylmethyl carbamate. 20. The compound of claim 17 wherein the amino protecting group is an amide group. 21. The compound of claim 20 wherein the amide group is selected from formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, pent-4-enamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl, benzamide, and p-phenylbenzamide.